Table 2 -.
Clinical Characteristics of 5-ALA and SWIG
| Characteristic | 5-ALA | Second Window ICG |
|---|---|---|
| Excitation/Emission Spectrum | 400–410nm / 635nm | 805nm / 835nm |
| Route of Administration | Oral | Intravenous |
| Timing of Administration | 3–4 hours Preoperative | 24 hours Preoperative |
| Major Contraindications | Porphyria, Pregnancy | Iodide Allergy, Pregnancy |
| Adverse Events | Photosensitivity for 2–3 Days Postoperatively | Infusion Site Irritation, Urticaria |
| Preclinical Tumor Accuracy | 80.5% | 89.0% |
| Fluorescence within Necrotic Tissue | Minimal | Equivalent to Neoplastic Tissue |
| Tumor Visualization through Intact Dura or Tissue | Not possible | Possible |
| Real-time Overlay of Fluorescence Signal | Not commercially available | Available |
| Visibility through Optics of Neurosurgical Microscopes | Yes | No |